5 82

Cited 2 times in

Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency

Authors
 Jin Soon Hwang ; Hae Sang Lee ; Sei Won Yang ; Duk-Hee Kim ; Yoon Ju Bae ; Jin-Hwa Lee ; Hyi-Jeong Ji ; Han-Wook Yoo ; Byung-Kyu Suh ; Jeh-Hoon Shin ; Kee-Hyoung Lee ; Dae-Yeol Lee ; Byung-Churl Lee ; Cheol-Woo Ko ; Ho-Seong Kim ; Dong-Kyu Jin ; Heon-Seok Han ; Woo Yeong Chung 
Citation
 European Journal of Endocrinology, Vol.169(2) : 179~185, 2013 
Journal Title
 European Journal of Endocrinology 
ISSN
 0804-4643 
Issue Date
2013
Abstract
PURPOSE: The purpose of this study was to investigate the efficacy and safety of LB03002, a sustained-release human GH (SR-hGH), compared with that of daily rhGH for 12 months in children with GH deficiency (GHD). METHODS: A total of 73 children with GHD were screened and 63 eligible subjects were randomized in a 1:1 ratio of LB03002 (SR-hGH) to daily rhGH treatment group. LB03002 was administered once weekly at a dose of 0.5 mg/kg while daily rhGH was administered for 6 consecutive days with equally divided doses to make a total of 0.21 mg/kg per week. Treatments were given for 12 months by s.c. injections. Injection site reactions and adverse events were investigated throughout the study period. RESULTS: The mean (S.D.) height velocity (HV) SHOWED a clinically significant increase after the 6-month treatment: 3.00 (1.15) cm/year at screening to 9.78 (1.98) cm/year at 6 months in the LB03002 group; 2.39 (1.63) cm/year at screening to 10.56 (2.65) cm/year at 6 months in the daily rhGH group. The increased HV at 12 months was still maintained in both the groups: 9.06 (1.63) cm/year at 12 months in the LB03002 group; 9.72 (2.32) cm/year at 12 months in the daily rhGH group. Most of the adverse drug reactions were mild and tolerable. No subjects were withdrawn due to adverse events. CONCLUSION: Weekly injection of LB03002 at a dose of 0.5 mg/kg per week was confirmed to have comparable efficacy to daily injection of rhGH at a dose of 0.21 mg/kg per week. Both formulations were well tolerated.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/88438
DOI
10.1530/EJE-13-0148
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Pediatrics
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://eje-online.org/content/169/2/179.long
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse